Politico, April 29, 2016. We explain why the REGROW Act is an effort to short-circuit the FDA’s “gold standard” for drug approvals and why it shows “a lack of understanding of the importance of well-designed research.”
May 2016, AJPH. Even before Nicolas Kristof asked why presidential candidates are ignoring women’s health, our guest editorial asked the candidates to ask women what they want in health care.
American Health Line, April 19, 2016. Patient safety experts, including Dr. Diana Zuckerman, report that the the Senate’s version of the House-approved 21st Century Cures Act has been updated but still needs more changes.
General Surgery News, April 12, 2016. The FDA approves or clears thousands of new medical devices each year. This highly complex process of review has garnered criticism in recent years. Dr. Diana Zuckerman weighs in on the lack of quality of clinical testing and the FDA approval process.
Medical Design Technology, April 4, 2016. The National Center for Health Research expresses that Advancing Breakthrough Devices for Patients Act of 2015 encourages companies to get medical products on the market quickly as opposed to focusing on patient safety and product efficiency.
Medscape Medical News, March 29, 2016. Dr Diana Zuckerman explains that publication delays of drug watch lists illustrate how the FDA caters more to drug manufacturers than patients.